Sionna Therapeutics, Inc./$SION
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Sionna Therapeutics, Inc.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Ticker
$SION
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
48
Website
SION Metrics
BasicAdvanced
$739M
-
-$6.81
-
-
Price and volume
Market cap
$739M
52-week high
$21.94
52-week low
$7.26
Average daily volume
225K
Financial strength
Current ratio
28.727
Quick ratio
28.305
Long term debt to equity
2.382
Total debt to equity
2.7
Profitability
EBITDA (TTM)
-76.407
Management effectiveness
Valuation
Price to book
2.1
Price to tangible book (TTM)
2.1
Price to free cash flow (TTM)
-2.914
Free cash flow yield (TTM)
-34.32%
Free cash flow per share (TTM)
-5.752
Growth
Bulls say / Bears say
Sionna Therapeutics reported positive Phase 1 data for its NBD1 stabilizers SION-719 and SION-451, indicating both compounds were well tolerated and achieved desired pharmacokinetic targets, supporting their potential as add-ons to standard cystic fibrosis treatments. (sionnatx.com)
The company completed an upsized IPO in February 2025, raising approximately $219 million in gross proceeds, bolstering its financial position to support ongoing and future clinical developments. (biospace.com)
Analysts at Guggenheim initiated coverage on Sionna Therapeutics with a 'buy' rating and a $45.00 price target, suggesting significant upside potential from the current stock price. (americanbankingnews.com)
Sionna Therapeutics reported a net loss of $16.5 million for the first quarter of 2025, reflecting ongoing expenses associated with its clinical-stage programs. (sionnatx.com)
The company's reliance on successful clinical outcomes for its NBD1 stabilizers poses a risk; any setbacks in clinical trials could negatively impact investor confidence and stock performance. (sionnatx.com)
Despite positive analyst coverage, the stock has experienced volatility, with a 52-week range between $13.20 and $25.19, indicating potential instability in investor sentiment. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sionna Therapeutics, Inc. stock?
Sionna Therapeutics, Inc. (SION) has a market cap of $739M as of August 01, 2025.
What is the P/E ratio for Sionna Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Sionna Therapeutics, Inc. (SION) stock is 0 as of August 01, 2025.
Does Sionna Therapeutics, Inc. stock pay dividends?
No, Sionna Therapeutics, Inc. (SION) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Sionna Therapeutics, Inc. dividend payment date?
Sionna Therapeutics, Inc. (SION) stock does not pay dividends to its shareholders.
What is the beta indicator for Sionna Therapeutics, Inc.?
Sionna Therapeutics, Inc. (SION) does not currently have a Beta indicator.